Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2004, p. 3543-3551, Vol. 48, No. 9
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.9.3543-3551.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects
Philip Krieter,1 Brian Flannery,1 Timothy Musick,2 Mark Gohdes,2 Monika Martinho,1 and Rachel Courtney1*
Schering-Plough Research Institute, Kenilworth, New Jersey,1
Covance Laboratories, Madison, Wisconsin2
Received 5 November 2003/
Returned for modification 30 December 2003/
Accepted 2 April 2004
Posaconazole is a potent, broad-spectrum triazole antifungal agent currently in clinical development for the treatment of refractory invasive fungal infections. Eight healthy male subjects received a single 399-mg (81.7 µCi) oral dose of [14C]posaconazole after consuming a high-fat breakfast. Urine, feces, and blood samples were collected for up to 336 h postdose and assayed for total radioactivity; plasma and urine samples were also assayed for parent drug. Posaconazole was orally bioavailable, with a median maximum posaconazole concentration in plasma achieved by 10 h postdose. Thereafter, posaconazole was slowly eliminated, with a mean half-life of 20 h. The greatest peak in the radioactivity profile of pooled plasma extracts was due to posaconazole, with smaller peaks due to a monoglucuronide, a diglucuronide, and a smaller fragment of the molecule. The mean total amount of radioactivity recovered was 91.1%; the cumulative excretion of radioactivity in feces and in urine was 76.9 and 14.0% of the dose, respectively. Most of the fecal radioactivity was associated with posaconazole, which accounted for 66.3% of the administered dose; however, urine contained only trace amounts of unchanged posaconazole. The radioactivity profile of pooled urine extracts included two monoglucuronide conjugates and a diglucuronide conjugate of posaconazole. These observations suggest that oxidative (phase 1) metabolism by cytochrome P450 isoforms represents only a minor route of elimination for posaconazole, and therefore cytochrome P450-mediated drug interactions should have a limited potential to impact posaconazole pharmacokinetics.
* Corresponding author. Mailing address: Early Clinical Research and Experimental Medicine, Schering-Plough Research Institute, K-15-4-4455, 2015 Galloping Hill Rd., Kenilworth, NJ 07033. Phone: (908) 740-3836. Fax: (908) 740-2169. E-mail: rachel.courtney{at}spcorp.com.
Antimicrobial Agents and Chemotherapy, September 2004, p. 3543-3551, Vol. 48, No. 9
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.9.3543-3551.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Hachem, R. Y., Langston, A. A., Graybill, J. R., Perfect, J. R., Pedicone, L. D., Patino, H., Raad, I. I.
(2008). Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother
62: 1386-1391
[Abstract]
[Full Text]
-
Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H
(2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy
42: 1429-1438
[Abstract]
[Full Text]
-
Goodwin, M. L., Drew, R. H.
(2008). Antifungal serum concentration monitoring: an update. J Antimicrob Chemother
61: 17-25
[Abstract]
[Full Text]
-
Omura, K., Nakazawa, T., Sato, T., Iwanaga, T., Nagata, O.
(2007). Characterization of N-Glucuronidation of 4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): A New Xanthine Oxidoreductase Inhibitor. Drug Metab. Dispos.
35: 2143-2148
[Abstract]
[Full Text]
-
Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L.
(2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother.
51: 812-818
[Abstract]
[Full Text]
-
Sansone-Parsons, A., Krishna, G., Simon, J., Soni, P., Kantesaria, B., Herron, J., Stoltz, R.
(2007). Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers. Antimicrob. Agents Chemother.
51: 495-502
[Abstract]
[Full Text]
-
Nakazawa, T., Miyata, K., Omura, K., Iwanaga, T., Nagata, O.
(2006). Metabolic Profile of FYX-051 (4-(5-Pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the Rat, Dog, Monkey, and Human: Identification of N-Glucuronides and N-Glucosides. Drug Metab. Dispos.
34: 1880-1886
[Abstract]
[Full Text]
-
Meletiadis, J., Chanock, S., Walsh, T. J.
(2006). Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. Clin. Microbiol. Rev.
19: 763-787
[Abstract]
[Full Text]
-
Gubbins, P. O., Krishna, G., Sansone-Parsons, A., Penzak, S. R., Dong, L., Martinho, M., Anaissie, E. J.
(2006). Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.. Antimicrob. Agents Chemother.
50: 1993-1999
[Abstract]
[Full Text]
-
Sansone-Parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M. A., Saltzman, M. A.
(2006). Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers.. Antimicrob. Agents Chemother.
50: 1881-1883
[Abstract]
[Full Text]
-
Courtney, R., Sansone, A., Smith, W., Marbury, T., Statkevich, P., Martinho, M., Laughlin, M., Swan, S.
(2005). Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease. J Clin Pharmacol
45: 185-192
[Abstract]
[Full Text]
Copyright © 2004 by the American Society for Microbiology. All rights reserved.